Verastem reported $18.67M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
AstraZeneca USD 16.21B 830M Sep/2026
Curis USD 1.14M 1.41M Dec/2025
Cytokinetics USD 47.6M 19M Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Laboratory Of America USD 3.81B 80M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
TG Therapeutics USD 259.94M 19.6M Sep/2026
Verastem USD 18.67M 1.14M Mar/2026